FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590753005> ?p ?o ?g. }

• W2590753005 endingPage "e15077" @default.
• W2590753005 startingPage "e15077" @default.
• W2590753005 abstract "e15077 Background: The effects of JI-101 on the pharmacokinetics (PK) of everolimus and vice versa were investigated in an open-label single sequence cross over study. This was the first clinical study done with JI-101 and another agent. Methods: Four Caucasian men ( prostate cancer=3, renal cell carcinoma=1) were enrolled with a median age of 70 yrs (range 65-80). Each received single-agent 10 mg everolimus on day 1, 10 mg everolimus and 200 mg JI-101 combination on day 8 and single-agent 200 mg of JI-101 on day 15. All patients had adequate organ function and ECOG performance status <2. Serial plasma samples were collected for PK evaluations on Days 1, 8, and 15 (pre dose and at 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after dosing each day). Plasma everolimus and JI-101 concentrations were measured by LC-MS-MS. PK parameters were estimated by using non-compartmental analysis. Results: No serious adverse events were observed. A single dose of JI-101 increased exposure (AUC0-inf in ng*hr/mL), of everolimus by approximately 22% in 3 patients However, in the 4th patient (aged 80 yrs) exposure increased by 3-fold with a concomitant 2-fold increase in half life (t ½ ) of everolimus. Examination of historic PK data of JI-101 suggested that age may be a factor to explain the interaction in this patient. No consistent trend was observed for the JI-101 exposure with everolimus (-41 to +38%). Conclusions: 1) Limited data suggests that dose reduction of JI-101 might be necessary when combining with everolimus. 2) A decrease in hepatic metabolism that occurs with age may have influenced the observed interaction. 3) A phase I combination study should be performed to further understand the PK and clinical safety of JI-101 with 10 mg everolimus. Change in PK parameters on coadministration of everolimus and JI-101. Change in PK parameters of everolimus Subject Age Everolimus AUC 0 to inf (ng.h/mL) Everolimus T ½ (h) 1 70 370 402 9 19.4 18 2 65 210 300 43 19.7 21.5 3 71 468 529 13 17.1 17.6 4 80 304 906 198 17.8 37.0 Change in PK parameters of JI-101 Subject Age JI-101 AUC 0 to inf (ng.h/mL) JI-101 T ½ (h) 1 70 4,462 6,109 37 8.4 22.2 2 65 4,785 2,847 -41 10.2 10.2 3 71 2,030 2,322 14 6.4 8.1 4 80 24,565 33,781 38 67.7 128.3" @default.
• W2590753005 created "2017-03-03" @default.
• W2590753005 creator A5005572303 @default.
• W2590753005 creator A5010236560 @default.
• W2590753005 creator A5023761882 @default.
• W2590753005 creator A5048752531 @default.
• W2590753005 creator A5080507578 @default.
• W2590753005 creator A5086203591 @default.
• W2590753005 creator A5090721087 @default.
• W2590753005 date "2011-05-20" @default.
• W2590753005 modified "2023-09-26" @default.
• W2590753005 title "A drug–drug interaction study of everolimus (an mTOR inhibitor) and JI-101, an orally active inhibitor of VEGF 2, PDGF, and EphB4 receptors, in patients with advanced urologic tumors." @default.
• W2590753005 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.e15077" @default.
• W2590753005 hasPublicationYear "2011" @default.
• W2590753005 type Work @default.
• W2590753005 sameAs 2590753005 @default.
• W2590753005 citedByCount "2" @default.
• W2590753005 countsByYear W25907530052012 @default.
• W2590753005 countsByYear W25907530052020 @default.
• W2590753005 crossrefType "journal-article" @default.
• W2590753005 hasAuthorship W2590753005A5005572303 @default.
• W2590753005 hasAuthorship W2590753005A5010236560 @default.
• W2590753005 hasAuthorship W2590753005A5023761882 @default.
• W2590753005 hasAuthorship W2590753005A5048752531 @default.
• W2590753005 hasAuthorship W2590753005A5080507578 @default.
• W2590753005 hasAuthorship W2590753005A5086203591 @default.
• W2590753005 hasAuthorship W2590753005A5090721087 @default.
• W2590753005 hasConcept C112705442 @default.
• W2590753005 hasConcept C126322002 @default.
• W2590753005 hasConcept C126894567 @default.
• W2590753005 hasConcept C143998085 @default.
• W2590753005 hasConcept C197934379 @default.
• W2590753005 hasConcept C2777288759 @default.
• W2590753005 hasConcept C2779384505 @default.
• W2590753005 hasConcept C2779699572 @default.
• W2590753005 hasConcept C71924100 @default.
• W2590753005 hasConcept C90924648 @default.
• W2590753005 hasConcept C98274493 @default.
• W2590753005 hasConceptScore W2590753005C112705442 @default.
• W2590753005 hasConceptScore W2590753005C126322002 @default.
• W2590753005 hasConceptScore W2590753005C126894567 @default.
• W2590753005 hasConceptScore W2590753005C143998085 @default.
• W2590753005 hasConceptScore W2590753005C197934379 @default.
• W2590753005 hasConceptScore W2590753005C2777288759 @default.
• W2590753005 hasConceptScore W2590753005C2779384505 @default.
• W2590753005 hasConceptScore W2590753005C2779699572 @default.
• W2590753005 hasConceptScore W2590753005C71924100 @default.
• W2590753005 hasConceptScore W2590753005C90924648 @default.
• W2590753005 hasConceptScore W2590753005C98274493 @default.
• W2590753005 hasIssue "15_suppl" @default.
• W2590753005 hasLocation W25907530051 @default.
• W2590753005 hasOpenAccess W2590753005 @default.
• W2590753005 hasPrimaryLocation W25907530051 @default.
• W2590753005 hasRelatedWork W1982989998 @default.
• W2590753005 hasRelatedWork W1988546203 @default.
• W2590753005 hasRelatedWork W2004325424 @default.
• W2590753005 hasRelatedWork W2051764329 @default.
• W2590753005 hasRelatedWork W2053610024 @default.
• W2590753005 hasRelatedWork W2075595860 @default.
• W2590753005 hasRelatedWork W2088748089 @default.
• W2590753005 hasRelatedWork W2093026976 @default.
• W2590753005 hasRelatedWork W2258567263 @default.
• W2590753005 hasRelatedWork W2793520024 @default.
• W2590753005 hasVolume "29" @default.
• W2590753005 isParatext "false" @default.
• W2590753005 isRetracted "false" @default.
• W2590753005 magId "2590753005" @default.
• W2590753005 workType "article" @default.